Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasm, Residual 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 69Paclitaxel 47Radiotherapy 44Pemetrexed 42Cisplatin 41Bevacizumab 36Gemcitabine 27Docetaxel 27Erlotinib Hydrochloride 23Gefitinib 18pembrolizumab 14Taxes 13Vinorelbine 10Cetuximab 10Radiation 8Nivolumab 8Magnetic Resonance Spectroscopy 8Radiosurgery 7Platinum 7Etoposide 7Surgical Procedures, Operative 6Radiotherapy, Conformal 6ceritinib 5capmatinib 5aflutinib 5Specimen Handling 5Neoadjuvant Therapy 5Mastectomy, Segmental 5Cyclophosphamide 5tislelizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Adenocarcinoma of Lung × AST5902 × Clear all
NCT05079022 2021-10-15

ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas

Peking University People's Hospital

Phase 1/2 Unknown
50 enrolled
Thoracic

Adenocarcinoma of Lung, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡